In the Spotlight...
There are no spotlights this week
Previous Digests
Flt3L fuels DCs to promote ICB-responsive Tpex cells
February 25, 2026
An important predictor of response to immune checkpoint blockade (ICB) is the presence of precursor exhausted T cells (Tpex) in the tumor. Conventional type 1 DCs (cDC1) are known to maintain these Tpex, and modulation of these factors might...
Deep and durable T cell responses after oncolytic viral therapy in glioblastoma
February 18, 2026
In a recent clinical trial, patients with glioblastoma (GBM) were treated with a single dose of an oHSV-1-based oncolytic viral therapy, rQNestin34.5v.2 (CAN-3110, linoserpaturev), in which expression of the viral ICP34.5 gene was controlled by the nestin promoter, overexpressed...
Good things come in threes: results from clinical trials to improve checkpoint blockade
February 11, 2026
Immune checkpoint blockade (ICB) has become a staple in the treatment of numerous cancers, but its efficacy could still be improved. Recently, three separate clinical trials explored strategies to improve ICB in the clinic. In one study, Duttagupta, Messaoudene...
Watch ACIR in action
In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.
Watch the 3-minute video explaining ACIR's mission and goal:
In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.
Watch the 6-minute segment on the story behind your favorite digest here:
About ACIR
ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.
Ute Burkhardt
Ed Fritsch
Lauren Hitchings
Gaëlle Llambi
Maartje Wouters
Alex Najibi
Katherine J. Turner
Stan Wolf
Paula Hochman
Shishir Pant
Nathan Suek
Morgan Janes
TESTIMONIALS
I'm a big fan of ACIR. I enjoy their weekly newsletters with clear, concise, and insightful summaries, complemented by excellent images. I've even used the images in some of my presentations to explain complex cancer immunotherapy findings. In our rapidly evolving field, their reliable and well-curated updates are invaluable.
Richard W. Vague Professor in Immunotherapy; Professor of PL&M; Director, Center for Cellular Immunotherapies; Director, Parker Institute for Cancer Immunotherapy; University of Pennsylvania Perelman School of Medicine. (Supporter since 2025).
Current Sponsors
